Details for Patent: 10,806,733

Which drugs does patent 10,806,733 protect, and when does it expire?

Patent 10,806,733 protects OXBRYTA and is included in two NDAs.

This patent has seventy-eight patent family members in thirty countries.

Summary for Patent: 10,806,733

Patent landscape, scope, and claims:

Title:	Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Abstract:	Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
Inventor(s):	Metcalf; Brian (South San Francisco, CA), Chuang; Chihyuan (South San Francisco, CA)
Assignee:	Global Blood Therapeutics, Inc. (South San Francisco, CA)
Application Number:	16/017,248
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 10,806,733

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Global Blood Theraps	OXBRYTA	voxelotor	TABLET, FOR SUSPENSION;ORAL	216157-001	Dec 17, 2021		DISCN	Yes	No	10,806,733			Y
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137-002	Oct 14, 2022		DISCN	Yes	No	10,806,733			Y
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137-001	Nov 25, 2019		DISCN	Yes	No	10,806,733			Y

International Family Members for US Patent 10,806,733

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2797416		301191	Netherlands
European Patent Office	2797416		CA 2022 00032	Denmark
European Patent Office	2797416		PA2022517	Lithuania
European Patent Office	2797416		122022000052	Germany
European Patent Office	2797416		LUC00276	Luxembourg